MedTrace Logo

A First-in-Human Phase 1 Single-Ascending Dose Study of ABCL575 in Healthy Participants

NCT07108894 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-23

No results posted yet for this study

Summary

This study aims to assess the safety and tolerability of ABCL575 in healthy participants following single ascending dose (SAD), in comparison to a placebo

Conditions

  • Healthy Volunteers

Interventions

BIOLOGICAL

ABCL575

Participants will receive SC injection of ABCL575

BIOLOGICAL

Placebo (Normal Saline 0.9%)

Participants will receive SC injection of placebo (Normal Saline 0.9%)

Sponsors & Collaborators

  • AbCellera Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • Eric Sicard · Altasciences Company Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-25
Primary Completion
2027-04-30
Completion
2027-04-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07108894 on ClinicalTrials.gov